Katherine G. Moss

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Medicine, Oncology, Pharmacology +15

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Charity Atkins, Qi Liu, Elisabeth A. Minthorn et al. · Cancer Research · 2013 · 429 citations

Medicine, Oncology, Pharmacology +14

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 258 citations · Full text

Medicine, Oncology, Pharmacology +17

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 217 citations · Full text

Medicine, Oncology, Pharmacology +16